Supernus Pharmaceuticals (SUPN) Total Non-Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals has reported Total Non-Current Liabilities for 16 years, with the latest figure at $377.0 million in Q2 2026.

• Total Non-Current Liabilities for Q2 2026 came in at $377.0 million, up 21.33% year-over-year; the trailing twelve-month figure through Jun 2026 was $377.0 million (up 21.33% YoY), and the FY2025 annual result was $359.7 million, up 26.2% from the prior year.
• Total Non-Current Liabilities fell to $377.0 million in Q2 2026, from $404.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $826.3 million in Q1 2023 and troughed at $285.0 million in Q4 2024.
• A 5-year average of $453.7 million and a median of $340.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The widest annual swing landed in 2024, when Total Non-Current Liabilities tumbled 60.96%; it then jumped 41.11% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $761.3 million in 2022, then plunged by 60.24% to $302.7 million in 2023, then fell by 5.85% to $285.0 million in 2024, then climbed by 26.2% to $359.7 million in 2025, then increased by 4.82% to $377.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $377.0 million in Q2 2026, $404.4 million in Q1 2026, and $359.7 million in Q4 2025.